Dr Frederic Brandt has several claims to fame. He is, for instance, the largest user of injectable collagen and Botox - in the world. ‘I just love fillers!’ he tells me. And how. When we meet at his New York clinic he wastes no time in revealing that he regularly injects himself. continue reading...

Beverly Hills, CA (PRWEB) May 7, 2008 — Dr. Simon Ourian of Epione in Beverly Hills criticizes the claims made by the Italian National Research Council’s study that BOTOX® can move to the brain from the injection site. “BOTOX® has been used safely for more than 25 years with few complications. This fear is completely unwarranted and largely alarmist,” explains Dr. Ourian.

The Journal of Neuroscience article (A New Reason to Frown; April 12), draws inappropriate conclusions about the medical product BOTOX® (Botulinum Toxin Type A), how it works in treating millions of patients suffering from severe conditions and incorrectly calls into question its 19-year safety record. “Although the study makes for great eyebrow raising news the science behind the study is largely flawed,” says Dr. Ourian. continue reading...

WALTHAM, Mass., July 23 /PRNewswire/ — Millennium Research Group has conducted a detailed analysis of the therapeutic botulinum toxin (BTX) market in its Global Markets for Therapeutic Botulinum Toxin 2007 report. The analysis reveals that an increasing number of patients will receive BTX treatment for therapeutic use over the next five years in the US as there is an expanding range of indications which will drive the market to over $850 million by 2012; a 15% growth rate over 2006.

Toward the end of 2012, new therapeutic BTX indications are expected to be approved and reimbursed which will drive unit sales in the US. In 2009, Allergan anticipates that Botox will be approved for the treatment of chronic daily headache, a condition that affected nearly 2 million people in the US in 2003. continue reading...